CLINICAL-TRIALS OF RILUZOLE IN PATIENTS WITH ALS

Authors
MILLER RG BOUCHARD JP DUQUETTE P EISEN A GELINAS DF HARATI Y MUNSAT TL POWE L ROTHSTEIN J SALZMAN P SUFIT RL GUILLET P BENSIMON G DELUMEAU JC DURRLEMAN S LACOMBLEZ L LEIGH PN MEININGER V MALOTEAUX JM DELWAIDE C GIRARD M MASSE C BLIN O AZULAY JP BILLETURC F POUGET J BOUCHE P CAMU W CARLANDER B CLANET M ANGIBAUD G ARNEBES MC BENAZET M COURATIER P DESNUELLE C LAGUENY A ELLIE E DIB M ROZIER A SALACHAS F VIADER F DELAUNAY D DENGLER R GUTHER G TROGER M LUDOLPH A BACHUS R GERICKE C PRZUNTEK H LANGKAFEL M SCHIMRIGK K JOST WH OSTERHAGE J PRUDLO J MORA J CHAVERRI D SAENZ E JEFFERSON D ORPE V LANE RJM ORRELL RW LLOYD CM BARBIE T MITCHELL JD KILSHAW J PALL HS GOODWIN M SCHADY W DUNCAN S MOORE C RICKARDS C SHAW PJ PICKERING CB SWASH M GOOCH CL ECHOLS CW QUIEN A THORNELL B ROTHSTEIN JD CLAWSON L SUFIT R CASEY P
Citation
Rg. Miller et al., CLINICAL-TRIALS OF RILUZOLE IN PATIENTS WITH ALS, Neurology, 47(4), 1996, pp. 86-90
Citations number
18
Categorie Soggetti
Clinical Neurology
Journal title
Neurology → ACNP
ISSN journal
00283878
Volume
47
Issue
4
Year of publication
1996
Supplement
2
Pages
86 - 90
Database
ISI
SICI code
0028-3878(1996)47:4<86:CORIPW>2.0.ZU;2-0
Abstract
Two double-blinded, placebo-controlled clinical trials of riluzole hav e now been carried out in more than 1,100 patients with ALS. The resul ts of both studies show a modest benefit in prolonging survival that i s statistically significant. These results led to the availability of this drug by the Food and Drug Administration for use in the United St ates beginning in early 1996. This is the first drug that has been ava ilable for ALS. It begins a new era in both basic and clinical researc h in an attempt to find a cure for this disease.